Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 INSYS TherapeuticsAmarillo BiosciencesCannaPharmaRXTeligentBetterLife Pharma
SymbolNASDAQ:INSYOTCMKTS:AMAROTCMKTS:CPMDNASDAQ:TLGTOTCMKTS:BETRF
Price Information
Current PriceN/A$0.70$0.23$0.56$0.54
52 Week RangeN/AN/AN/AHoldN/A
MarketRank™
Overall Score1.00.50.31.20.0
Analysis Score0.00.00.03.00.0
Community Score2.72.60.03.00.0
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.00.0
Earnings & Valuation Score0.60.00.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AHoldN/A
Consensus Price TargetN/AN/AN/A$2.00N/A
% Upside from Price TargetN/AN/AN/A257.14% upsideN/A
Trade Information
Market Cap$21.71 million$29.45 million$12.44 million$12.18 million$10.84 million
Beta3.21-0.31.851.793.8
Average Volume9,520,59219,823142,3165,910,12283,527
Sales & Book Value
Annual Revenue$82.08 million$10,000.00N/A$65.90 millionN/A
Price / Sales0.002,944.62N/A0.18N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($0.58) per shareN/A$0.11 per share($0.99) per share$0.12 per share
Price / Book0.00N/A-0.57N/A
Profitability
Net Income$-124,510,000.00$-1,580,000.00$-20,450,000.00$-25,120,000.00$-14,780,000.00
EPS($1.39)N/AN/AN/AN/A
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-346.61%-7,434.30%N/A-91.50%N/A
Return on Equity (ROE)-1,430.37%N/A-726.81%N/A-734.15%
Return on Assets (ROA)-64.04%-320.19%-96.06%-17.52%-219.66%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A7.78%N/AN/A
Current Ratio0.54%0.15%0.03%2.48%0.16%
Quick Ratio0.50%0.14%0.03%1.25%0.16%
Ownership Information
Institutional Ownership Percentage14.93%N/AN/A28.15%N/A
Insider Ownership Percentage65.40%N/A71.90%2.09%34.77%
Miscellaneous
Employees226242527
Shares Outstanding74.57 million42.07 million52.04 million21.75 million17.21 million
Next Earnings DateN/A5/21/2021 (Estimated)7/5/2021 (Estimated)5/28/2021 (Estimated)6/7/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
BetterLife Pharma Inc. (OTCMKTS:BETRF) Short Interest Up 3,000.0% in MarchBetterLife Pharma Inc. (OTCMKTS:BETRF) Short Interest Up 3,000.0% in March
americanbankingnews.com - April 13 at 5:14 AM
Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory AdvisorFormer FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor
finance.yahoo.com - April 8 at 12:27 PM
BetterLife Added to Horizons Psychedelic Stock Index ETFBetterLife Added to Horizons Psychedelic Stock Index ETF
finance.yahoo.com - March 29 at 9:31 AM
Short Interest in BetterLife Pharma Inc. (OTCMKTS:BETRF) Declines By 61.5%Short Interest in BetterLife Pharma Inc. (OTCMKTS:BETRF) Declines By 61.5%
americanbankingnews.com - March 28 at 8:06 AM
BetterLife Pharma says subsidiary Altum Pharmaceuticals to conduct coronavirus trial in Chile using its AP-003BetterLife Pharma says subsidiary Altum Pharmaceuticals to conduct coronavirus trial in Chile using its AP-003
proactiveinvestors.com - March 26 at 8:56 PM
BetterLife Pharma inks research agreement with the University of California San DiegoBetterLife Pharma inks research agreement with the University of California San Diego
proactiveinvestors.com - March 26 at 8:56 PM
BetterLife Pharma: BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology StudiesBetterLife Pharma: BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology Studies
finanznachrichten.de - March 24 at 12:53 PM
BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology StudiesBetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology Studies
finance.yahoo.com - March 24 at 12:53 PM
BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003
finance.yahoo.com - March 11 at 12:21 PM
BetterLife Pharma announces tie-up with Carleton University to study TD-0148A as treatment for depressionBetterLife Pharma announces tie-up with Carleton University to study TD-0148A as treatment for depression
proactiveinvestors.com - March 10 at 8:32 AM
BetterLife Enters Research Agreement with Carleton University for TD-0148A Depression StudiesBetterLife Enters Research Agreement with Carleton University for TD-0148A Depression Studies
finance.yahoo.com - March 8 at 8:09 AM
Proactive news headlines including BetterLife Pharma, HempFusion Wellness, Pure Gold Mining,Proactive news headlines including BetterLife Pharma, HempFusion Wellness, Pure Gold Mining,
apnews.com - March 5 at 12:24 AM
BetterLife engages Eurofins CDMO for psychedelic TD-0148A manufacturingBetterLife engages Eurofins CDMO for psychedelic TD-0148A manufacturing
canadianinvestor.com - March 3 at 7:51 PM
BetterLife Pharma hires Eurofins CDMO to manufacture LSD derivative TD-0148ABetterLife Pharma hires Eurofins CDMO to manufacture LSD derivative TD-0148A
proactiveinvestors.com - March 3 at 2:50 PM
BetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A ManufacturingBetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A Manufacturing
finance.yahoo.com - March 3 at 9:50 AM
BetterLife Pharma files patent protection for its newest compound TD-010 to treat anxiolytic-use disorderBetterLife Pharma files patent protection for its newest compound TD-010 to treat anxiolytic-use disorder
proactiveinvestors.com - February 2 at 12:29 PM
BetterLife Files Patent Protection on Dihydrohonokiol-B for Treatment of Anxiolytic Use DisorderBetterLife Files Patent Protection on Dihydrohonokiol-B for Treatment of Anxiolytic Use Disorder
finance.yahoo.com - February 2 at 12:29 PM
BetterLife Pharma inhaled coronavirus treatment passes six months of cold temperature testsBetterLife Pharma inhaled coronavirus treatment passes six months of cold temperature tests
proactiveinvestors.com - January 28 at 8:16 PM
BetterLife Pharma partners with Eurofins Discovery for pharmacology studies of Eurofins LSD-derived molecule TD-0148ABetterLife Pharma partners with Eurofins Discovery for pharmacology studies of Eurofins' LSD-derived molecule TD-0148A
proactiveinvestors.com - January 28 at 10:15 AM
BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA ...BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA ...
apnews.com - January 28 at 5:15 AM
BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon ...BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon ...
apnews.com - January 26 at 11:23 AM
BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 CasesBetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 Cases
benzinga.com - January 26 at 11:23 AM
BetterLife Pharma inhaled coronavirus treatment passes six months of cold temperture testsBetterLife Pharma inhaled coronavirus treatment passes six months of cold temperture tests
proactiveinvestors.com - January 26 at 11:23 AM
BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in IndonesiaBetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia
benzinga.com - January 21 at 9:33 AM
BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in IndonesiaBetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia
finance.yahoo.com - January 21 at 9:33 AM
DateCompanyBrokerageAction
5/14/2019INSYS TherapeuticsJanney Montgomery ScottDowngrade
3/8/2019INSYS TherapeuticsPiper Jaffray CompaniesSet Price Target
3/8/2019INSYS TherapeuticsRoyal Bank of CanadaLower Price Target
1/22/2019INSYS TherapeuticsCantor FitzgeraldInitiated Coverage
8/10/2018INSYS TherapeuticsJefferies Financial GroupReiterated Rating
5/9/2018INSYS TherapeuticsOppenheimerReiterated Rating
8/20/2020TeligentCraig HallumDowngrade
10/3/2019TeligentRaymond JamesDowngrade
11/16/2018TeligentCanaccord GenuityLower Price Target
(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.